Showing 241 - 260 results of 20,223 for search '(( significantly ((i decrease) OR (a decrease)) ) OR ( significant increase decrease ))', query time: 0.86s Refine Results
  1. 241
  2. 242
  3. 243
  4. 244
  5. 245
  6. 246
  7. 247
  8. 248

    S1 Data - by Miki Doi (15347878)

    Published 2024
    Subjects:
  9. 249

    S1 Fig - by Miki Doi (15347878)

    Published 2024
    Subjects:
  10. 250
  11. 251
  12. 252
  13. 253
  14. 254
  15. 255
  16. 256

    HFD decreases intermediate-term memory. by Tong Yue (6033305)

    Published 2025
    “…Error bars indicate SD (n = 3. Student’s <i>t</i>-test, * p < 0.05). (C) Food intake was not significantly different between ND- and HFD-fed flies during the 1 hour. …”
  17. 257
  18. 258

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  19. 259

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  20. 260